Andere Sprachen Exact Sciences Corporation

Aktien

590273

US30063P1057

EXAS

Biotechnologie

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:27:39 22.04.2025			% 5 Tage	% 1. Jan.
44.22 ^USD	+2.61%		+0.29%	-21.02%

12:00	Exact Sciences bringt den Oncodetect-Test zur molekularen Restkrankheitsdiagnostik auf den Markt	CI
14.04.	Exact Sciences Corp. gibt die Veröffentlichung eines umfassenden Berichts in JAMA Oncology bekannt, der die Evidenz für den Oncotype DX Breast Recurrence Score Test stärkt	CI

Andere Sprachen

Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test	12:04
Exact Sciences Launches the Oncodetect Molecular Residual Disease Test	12:00
Exact Sciences Corp. - JAMA Oncology Publication Strengthens Evidence for Oncotype DX Test Reliability across Racial and Ethnic Groups	15.04.
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups	14.04.
Exact Sciences Corp. Announces Publication of Comprehensive Review in JAMA Oncology That Strengthens the Evidence Supporting the Oncotype DX Breast Recurrence Score Test	14.04.
Exact Sciences Schedules First Quarter 2025 Earnings Call	01.04.
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening	31.03.
Exact Sciences Corp. Launches the Cologuard Plus?? Test, Transforming Colorectal Cancer Screening	31.03.
Consumer Spending and the Inflation Fear	28.03.
Analyst recommendations: Illumina, Boeing, Next, Walmart, Applovin....	28.03.
Sera Prognostics appoints Jeff Elliott to board	19.03.
Sera Prognostics Inc. Announces Board Changes	19.03.
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis	14.03.
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner	12.03.
Exact Sciences Corporation Announces the Presentation of New Data Further Confirming the Utility of Its Oncotype Dx Breast Recurrence Score®? Test At the 19thst. Gallen International Breast Cancer Conference in Vienna, Austria	12.03.
Exact Sciences to Participate in March Investor Conferences	24.02.
Exact Sciences Corp Plans To Launch Three New Cancer Tests In 2025	19.02.
Exact Sciences : Fourth Quarter 2024 Earnings Presentation	19.02.
Exact Sciences : Fourth Quarter 2024 Earnings Presentation	19.02.
Exact Sciences Corporation Provides Earnings Guidance for the First Quarter of 2025	19.02.
Exact Sciences: Q4 Earnings Snapshot	19.02.
Exact Sciences Q4 Net Loss Widens, Revenue Up; Sets Outlook	19.02.
Earnings Flash (EXAS) Exact Sciences Posts Q4 Revenue $713.4M, vs. FactSet Est of $701.9M	19.02.
Earnings Flash (EXAS) Exact Sciences Reports Q4 Loss $-0.06 Per Share	19.02.
Exact Sciences Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	19.02.

Keine Ergebnisse zu dieser Suche

Mehr Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Exact Sciences Corporation

Aktien

590273

US30063P1057

EXAS

Biotechnologie

Andere Sprachen

Filter